Ionis Pharmaceuticals announces FDA approval of Dawnzera

Ionis Pharmaceuticals (IONS) announced that the U.S. Food and Drug Administration has approved Dawnzera for prophylaxis to prevent attacks of hereditary angioedema in adult and pediatric patients 12 years of age and older. “Dawnzera is the first and only RNA-targeted medicine approved for HAE, designed to target plasma prekallikrein, a key protein that activates inflammatory mediators associated with acute attacks of HAE,” the company stated. Dawnzera 80mg is self-administered via subcutaneous autoinjector once every four or eight weeks. Dawnzera will be available in the U.S. in the coming days, the company stated.